FDA approves Dr Reddy’s Vascepa generic

Indian drugmaker Dr Reddy’s has won approval to launch just the second generic version of heart drug Vascepa (icosapent ethyl), in another blow for Amarin.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Judge allows Dr Reddy’s to add antitrust claims in Indivior dispute

25 August 2020 A district judge has given India-based Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against Indivior.

Big Pharma

Amarin vows to challenge Vascepa patent ruling

4 September 2020 Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa.

Americas

BMS and Dr Reddy’s settle Revlimid suit with generics licence

22 September 2020 Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid.

More on this story

Americas

Judge allows Dr Reddy’s to add antitrust claims in Indivior dispute

25 August 2020 A district judge has given India-based Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against Indivior.

Big Pharma

Amarin vows to challenge Vascepa patent ruling

4 September 2020 Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa.

Americas

BMS and Dr Reddy’s settle Revlimid suit with generics licence

22 September 2020 Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid.

More on this story

Americas

Judge allows Dr Reddy’s to add antitrust claims in Indivior dispute

25 August 2020 A district judge has given India-based Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against Indivior.

Big Pharma

Amarin vows to challenge Vascepa patent ruling

4 September 2020 Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa.

Americas

BMS and Dr Reddy’s settle Revlimid suit with generics licence

22 September 2020 Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility

FDA approves Dr Reddy’s Vascepa generic

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features